Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Karyopharm Therapeutics (KPTI) over the last 10 years, with Q4 2025 value amounting to $329.0 million.

  • Karyopharm Therapeutics' Total Non-Current Liabilities rose 1880.15% to $329.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $329.0 million, marking a year-over-year increase of 1880.15%. This contributed to the annual value of $329.0 million for FY2025, which is 1880.15% up from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Total Non-Current Liabilities is $329.0 million, which was up 1880.15% from $292.0 million recorded in Q3 2025.
  • Karyopharm Therapeutics' Total Non-Current Liabilities' 5-year high stood at $329.0 million during Q4 2025, with a 5-year trough of $236.4 million in Q2 2023.
  • Its 5-year average for Total Non-Current Liabilities is $255.8 million, with a median of $244.1 million in 2022.
  • Per our database at Business Quant, Karyopharm Therapeutics' Total Non-Current Liabilities surged by 3737.69% in 2021 and then tumbled by 391.7% in 2022.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Total Non-Current Liabilities stood at $252.0 million in 2021, then decreased by 3.92% to $242.1 million in 2022, then increased by 0.85% to $244.2 million in 2023, then increased by 13.42% to $276.9 million in 2024, then increased by 18.8% to $329.0 million in 2025.
  • Its Total Non-Current Liabilities was $329.0 million in Q4 2025, compared to $292.0 million in Q3 2025 and $270.3 million in Q2 2025.